Nevro Corp (NYSE:NVRO) Director Wilfred E. Jaeger sold 160,542 shares of the business’s stock in a transaction dated Wednesday, March 7th. The shares were sold at an average price of $80.77, for a total value of $12,966,977.34. Following the completion of the transaction, the director now directly owns 1,518 shares in the company, valued at $122,608.86. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Shares of Nevro Corp (NVRO) traded down $0.13 during trading on Wednesday, reaching $86.68. The company had a trading volume of 268,174 shares, compared to its average volume of 373,781. The company has a debt-to-equity ratio of 0.58, a current ratio of 7.61 and a quick ratio of 5.91. The company has a market cap of $2,590.45, a price-to-earnings ratio of -68.79 and a beta of -0.51. Nevro Corp has a twelve month low of $65.00 and a twelve month high of $97.70.
Nevro (NYSE:NVRO) last issued its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). The company had revenue of $97.96 million for the quarter, compared to the consensus estimate of $96.87 million. Nevro had a negative return on equity of 15.01% and a negative net margin of 11.22%. The business’s revenue for the quarter was up 38.9% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.34) earnings per share. sell-side analysts predict that Nevro Corp will post -0.76 earnings per share for the current fiscal year.
A number of research analysts have recently issued reports on the company. Zacks Investment Research downgraded Nevro from a “hold” rating to a “sell” rating in a research note on Wednesday, February 28th. ValuEngine lowered Nevro from a “hold” rating to a “sell” rating in a research report on Friday, February 2nd. BMO Capital Markets reaffirmed a “buy” rating and issued a $100.00 target price on shares of Nevro in a research report on Thursday, December 14th. Finally, BidaskClub lowered Nevro from a “sell” rating to a “strong sell” rating in a research report on Tuesday, November 14th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $99.25.
A number of institutional investors and hedge funds have recently modified their holdings of NVRO. OppenheimerFunds Inc. increased its holdings in Nevro by 50.0% during the 4th quarter. OppenheimerFunds Inc. now owns 900,594 shares of the medical equipment provider’s stock worth $62,177,000 after purchasing an additional 300,064 shares in the last quarter. First Manhattan Co. bought a new stake in Nevro during the 4th quarter worth approximately $15,630,000. Principal Financial Group Inc. increased its holdings in Nevro by 160.5% during the 3rd quarter. Principal Financial Group Inc. now owns 275,383 shares of the medical equipment provider’s stock worth $25,027,000 after purchasing an additional 169,683 shares in the last quarter. Jennison Associates LLC increased its holdings in Nevro by 12.6% during the 4th quarter. Jennison Associates LLC now owns 1,282,874 shares of the medical equipment provider’s stock worth $88,570,000 after purchasing an additional 143,962 shares in the last quarter. Finally, Point72 Asset Management L.P. increased its holdings in Nevro by 35.4% during the 3rd quarter. Point72 Asset Management L.P. now owns 542,952 shares of the medical equipment provider’s stock worth $49,343,000 after purchasing an additional 141,963 shares in the last quarter.
TRADEMARK VIOLATION NOTICE: This piece of content was published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.thelincolnianonline.com/2018/03/14/wilfred-e-jaeger-sells-160542-shares-of-nevro-corp-nvro-stock.html.
Nevro Company Profile
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.